Johnson & Johnson (JNJ)
Pre-market:
| Previous close | 146.97 |
| Open | 146.79 |
| Bid | 0.00 x 1400 |
| Ask | 0.00 x 1200 |
| Day's range | 144.15 - 146.79 |
| 52-week range | 143.13 - 175.97 |
| Volume | |
| Avg. volume | 7,530,011 |
| Market cap | 347.476B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 21.84 |
| EPS (TTM) | 6.61 |
| Earnings date | 17 Jul 2024 |
| Forward dividend & yield | 4.96 (3.37%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | 172.72 |
GlobeNewswireNumab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
J&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights NM26 is a Phase 2-ready bi-specific antibody from Numab’s pipeline of candidates, discovered and engineered using its proprietary MATCH™ technology platform HORGEN, Switzerland, May 28, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (Nu
Business WireJohnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
NEW BRUNSWICK, N.J., May 28, 2024--Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement with Numab Therapeutics, a clinical-stage biotechnology company advancing a pipeline of immunology and oncology therapeutics, to acquire from Numab's shareholders its wholly-owned subsidiary for the global rights to a novel, investigational first-in-class bispecific antibody, NM26, in an all-cash transaction of approximately $1.25 billion.
Zacks3 Top Dividend Stocks to Maximize Your Retirement Income
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
